7 news items
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
EXAS
MYNZ
5 Jun 24
.The company recently unveiled compelling findings from its most expansive group to date at the 2024 Annual Meeting of the American Society
Exact Sciences Says It Demonstrates Continued Leadership In Early Cancer Diagnosis And Improved Health Outcomes For Patients With Multiple Data Presentations At American Society Of Clinical Oncology Annual Meeting
EXAS
24 May 24
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
EXAS
24 May 24
and depth of the company's screening and diagnostic portfolio at the American Society of Clinical Oncology
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
EXAS
21 May 24
in March 2014. The Cologuard test is included in the American Cancer Society's (2018) colorectal cancer screening guidelines
Exact Sciences Announces First-Quarter 2024 Results
EXAS
8 May 24
Journal of Medicine in March 2014. The Cologuard test is included in the American Cancer Society's (2018) colorectal cancer screening guidelines
4suaulb1isn3or k8c4q
EXAS
7 May 24
in the New England Journal of Medicine in March 2014. The Cologuard test is included in the American Cancer Society's (2018) colorectal cancer screening
0jdqarleik69m1fub1xxt1 xd66vv29o
EXAS
8 Apr 24
#LB100/11, AACR 2024.
American Cancer Society. Cancer facts and figures 2024. Accessed April 3, 2024
- Prev
- 1
- Next